Published by Josh White on 9th December 2025
(Sharecast News) - Sareum updated investors on progress across its pipeline ahead of its annual general meeting on Tuesday, highlighting continued advances in its lead autoimmune candidate SDC-1801 and strengthening commercial positioning for its cancer assets SDC-1802 and SRA737.
URL: http://www.digitallook.com/dl/news/story/35550347/...